Premium
Inefficacy of selegiline in treatment of canine pituitary‐dependent hyper‐adrenocorticism
Author(s) -
BRADDOCK JA,
CHURCH DB,
ROBERTSON ID,
WATSON ADJ
Publication year - 2004
Publication title -
australian veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.382
H-Index - 59
eISSN - 1751-0813
pISSN - 0005-0423
DOI - 10.1111/j.1751-0813.2004.tb12702.x
Subject(s) - selegiline , medicine , pituitary disease , adrenocorticotropic hormone , monoamine oxidase , endocrinology , hormone , disease , parkinson's disease , biology , enzyme , biochemistry
Objective To evaluate selegiline, a monoamine oxidase‐B inhibitor, for treating dogs with pituitary‐dependent hyperadrenocorticism. Design Prospective clinical trial using client‐owned dogs with pituitary‐dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001. Procedure Eleven dogs with pituitary‐dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. Results No dog treated with selegiline had satisfactory control of disease. Conclusion Selegiline administration was safe and free of side‐effects at the doses used, but did not satisfactorily control disease in pituitary‐dependent hyperadrenocorticism affected dogs.